Mckesson Corporation & Affiliates U.S. Oncology and Rx Savings Solutions

Based in TX

🤖

AI Overview

With $22.7M in lobbying spend across 38 quarterly filings, Mckesson Corporation & Affiliates U.S. Oncology and Rx Savings Solutions is one of the biggest lobbying spenders in Washington. They deploy 17 individual lobbyists Their lobbying covers 7 issue areas. Active from 2018 to 2025.

$22.7M
Total Spend
8
Years Active
1
Firms Hired
17
Lobbyists Deployed
7
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2018$1.6M
2019$2.1M
2020$1.5M
2021$2.1M
2022$3.8M
2023$3.4M
2024$3.4M
2025$4.6M

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Mckesson Corporation & Affiliates U.S. Oncology and Rx Savings Solutions disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)HOUSE OF REPRESENTATIVESSENATEWhite House OfficeHealth & Human Services, Dept of (HHS)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: Taxation, Health Issues, Medicare/Medicaid, Pharmacy, Veterans and 2 more

H.R./S.1: Tax Cuts and Jobs Act.

Implementation of Comprehensive Addiction and Recovery Act (CARA) PL 114-198 and education regarding opioid treatment and prevention; Implementation of 21st Century Cures (H.R. 34), advocacy related t

Physician and pharmacy reimbursement issues;

Legislation to amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the

Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytics dispensed by commun

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.